Socomed Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-10-2024
- Paid Up Capital ₹ 4.86 M
as on 24-10-2024
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.53 Cr
as on 24-10-2024
- Revenue 33.01%
(FY 2023)
- Profit 148.29%
(FY 2023)
- Ebitda 139.88%
(FY 2023)
- Net Worth 46.06%
(FY 2023)
- Total Assets 16.80%
(FY 2023)
About Socomed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.86 M.
The company currently has active open charges totaling ₹2.53 Cr.
Aasif Dange and Bakhtawar Dange serve as directors at the Company.
- CIN/LLPIN
U24233MH2008PTC181516
- Company No.
181516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Socomed Pharma Private Limited offer?
Socomed Pharma Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anesthetic.
Who are the key members and board of directors at Socomed Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aasif Dange  | Director | 13-Dec-2011 | Current |
| Bakhtawar Dange | Director | 01-Oct-2021 | Current |
Financial Performance and Corporate Structure Insights of Socomed Pharma.
Socomed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 33.01% increase. The company also saw a substantial improvement in profitability, with a 148.29% increase in profit. The company's net worth Soared by an impressive increase of 46.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Socomed Pharma?
In 2023, Socomed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kind Health And Hygiene Private LimitedActive 11 years 28 daysAasif Dange and Bakhtawar Dange are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 22 Apr 2019 | ₹2.53 Cr | Open |
How Many Employees Work at Socomed Pharma?
Socomed Pharma has a workforce of 30 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Socomed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Socomed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
